Daniel Spiegelman
2016
In 2016, Daniel Spiegelman earned a total compensation of $4.9M as Executive Vice President, Chief Financial Officer at BioMarin Pharmaceutical, a 27% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $382,793 |
|---|---|
| Option Awards | $1,584,825 |
| Salary | $530,192 |
| Stock Awards | $2,380,258 |
| Other | $21,135 |
| Total | $4,899,203 |
Spiegelman received $2.4M in stock awards, accounting for 49% of the total pay in 2016.
Spiegelman also received $382.8K in non-equity incentive plan, $1.6M in option awards, $530.2K in salary and $21.1K in other compensation.
Rankings
In 2016, Daniel Spiegelman's compensation ranked 1,663rd out of 14,075 executives tracked by ExecPay. In other words, Spiegelman earned more than 88.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,663 out of 14,075 | 88th |
Division Manufacturing | 560 out of 5,489 | 90th |
Major group Chemicals And Allied Products | 158 out of 1,895 | 92nd |
Industry group Drugs | 108 out of 1,538 | 93rd |
Industry Pharmaceutical Preparations | 86 out of 1,176 | 93rd |
Source: SEC filing on April 25, 2017.
Spiegelman's colleagues
We found four more compensation records of executives who worked with Daniel Spiegelman at BioMarin Pharmaceutical in 2016.
2016
Jean-Jacques Bienaim
BioMarin Pharmaceutical
Chief Executive Officer
2016
Henry Fuchs
BioMarin Pharmaceutical
President, Worldwide R&D
2016
Robert Baffi
BioMarin Pharmaceutical
Executive Vice President, Technical Operations
2016
Jeff Ajer
BioMarin Pharmaceutical